| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9255261 | QOL MEDCL | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(9 years from now) | |
| US9849161 | QOL MEDCL | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(9 years from now) | |
| US9469847 | QOL MEDCL | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(9 years from now) | |
Sucraid is owned by Qol Medcl.
Sucraid contains Sacrosidase.
Sucraid has a total of 3 drug patents out of which 0 drug patents have expired.
Sucraid was authorised for market use on 09 April, 1998.
Sucraid is available in solution;oral dosage forms.
The generics of Sucraid are possible to be released after 07 February, 2034.
Drugs and Companies using SACROSIDASE ingredient
Market Authorisation Date: 09 April, 1998
Treatment: NA
Dosage: SOLUTION;ORAL
More Information on Dosage
SUCRAID family patents
